Drug Profile


Alternative Names: PledOx; PP-095

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator PledPharma
  • Class Acetates; Chemoprotectants; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chemoprotection

Most Recent Events

  • 20 Oct 2016 PledPharma announces intention to submit NDA and MAA to the US FDA and EMA
  • 20 Oct 2016 PledPharma plans two phase III trials for Colorectal cancer
  • 16 May 2016 Updated follow-up efficacy data from the phase I/II PLIANT study in Chemoprotection released by Pledpharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top